Clinical Trial Update: Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating tocilizumab for possible immunomodulatory effects in patients with refractory status epilepticus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Damanhour University | Conditions: Epilepsy | Phase 3 | Status: UNKNOWN